Pages that link to "Q54117344"
Jump to navigation
Jump to search
The following pages link to Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. (Q54117344):
Displaying 50 items.
- Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor (Q22253464) (← links)
- Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma (Q24316497) (← links)
- Cloning and characterization of a novel human histone deacetylase, HDAC8 (Q24532118) (← links)
- Histone deacetylases (HDACs): characterization of the classical HDAC family (Q24535587) (← links)
- ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain (Q24548340) (← links)
- Oligomerization of ETO is obligatory for corepressor interaction (Q24550754) (← links)
- Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway (Q24610640) (← links)
- Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia (Q24671020) (← links)
- Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer (Q26777453) (← links)
- Epigenomics of leukemia: from mechanisms to therapeutic applications (Q26823403) (← links)
- Trials with 'epigenetic' drugs: an update (Q27000542) (← links)
- One mouse, one patient paradigm: New avatars of personalized cancer therapy (Q27023342) (← links)
- Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells (Q28142463) (← links)
- The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase (Q28216000) (← links)
- Phosphorylation of Ser28 in histone H3 mediated by mixed lineage kinase-like mitogen-activated protein triple kinase alpha (Q28305184) (← links)
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells (Q28366303) (← links)
- Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro (Q28828149) (← links)
- Anticancer activities of histone deacetylase inhibitors (Q29616624) (← links)
- Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway (Q30310695) (← links)
- Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells (Q31858549) (← links)
- All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia (Q31922432) (← links)
- Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models (Q31922478) (← links)
- Cytodifferentiation: a novel approach to cancer treatment and prevention (Q33183127) (← links)
- In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia (Q33185196) (← links)
- Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents (Q33279222) (← links)
- Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation (Q33349703) (← links)
- Histone deacetylase inhibitor therapy in epithelial ovarian cancer (Q33568495) (← links)
- A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas (Q33619776) (← links)
- Molecular genetics of acute promyelocytic leukemia. (Q33633027) (← links)
- Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer (Q33651762) (← links)
- Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy. (Q33652165) (← links)
- The PML nuclear bodies: actors or extras? (Q33665836) (← links)
- Chromatin remodeling and transcriptional regulation (Q33703534) (← links)
- The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease (Q33723609) (← links)
- In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications (Q33739259) (← links)
- Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome (Q33741025) (← links)
- Organization of chromatin in cancer cells: role of signalling pathways (Q33765339) (← links)
- Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. (Q33783545) (← links)
- Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes (Q33846392) (← links)
- Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation (Q33862993) (← links)
- Retinoids in chemoprevention and differentiation therapy (Q33954693) (← links)
- Novel strategies and therapeutics for the treatment of prostate carcinoma (Q34043331) (← links)
- Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells (Q34055317) (← links)
- Targeted therapies for the myeloid leukaemias (Q34074884) (← links)
- Location and function of critical genes in leukemogenesis inferred from cytogenetic abnormalities in hematologic malignancies (Q34079213) (← links)
- Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors (Q34091001) (← links)
- Chromatin modification and disease (Q34098840) (← links)
- Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia (Q34108096) (← links)
- Histone deacetylase inhibitors: novel anticancer agents (Q34119504) (← links)
- Future perspectives for acute promyelocytic leukemia therapy (Q34137347) (← links)